coadministered cagrilintide and semaglutide in adults with overweight or obesity Summary of REDEFINE 1 REDEFINE 2 trials CagriSema, presented this week at #ADA2025 and published NEJM: REDEFINE 1: • 👥 3,417 participants with (without diabetes) treated Combined GLP-1/amylin analog bests monotherapy

The future of GLP-1RA therapy is promising

[1] For people with type 2 diabetes, maintaining consistent blood glucose control is crucial to prevent both short-term complications (such as hyperglycaemia) and long-term damage to blood vessels, nerves, kidneys, and eyes

These are not easy standards to meet

Research shows it stimulates the production of collagen types I, II, and III, plus elastin, dermatan sulfate, and decorin all of the structural proteins that keep skin firm

Total semaglutide used during this phase: 6.8 mg (4 injections of 1.7 mg) Cumulative total through week 16: 13.8 mg You are now into your second 10mg vial